Nevada Medicaid and semaglutide
Wegovy for weight loss: no. Prior authorization for heart risk in people with established heart disease and no diabetes, or for the liver condition MASH. Ozempic for weight loss: no; for type 2 diabetes Nevada Medicaid must cover it. Read from Nevada Health Authority, Nevada Medicaid documents Nov 6, 2026.
In 2025 Nevada Medicaid paid for 44,949 semaglutide prescriptions (Ozempic, Rybelsus, Wegovy), 63% of its GLP-1 prescriptions and 24th of the 50 states and DC. It reimbursed $48.6 million before rebates, $1,080 a prescription against $1,104 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Ozempic | 42,402 | $45.6 million | $1,076 |
| Rybelsus | 1,671 | $1.9 million | $1,133 |
| Wegovy | 876 | $1.1 million | $1,208 |
Nevada plans and prescribing rules
Nevada Public Employees' Benefits Program (PEBP). Nevada's PEBP provides weight-loss medications through its voluntary, opt-in Obesity Care Management Program, alongside medically supervised weight loss and nutritional counseling, per its plan year 2026 benefit guide.
Online prescribing. The Nevada State Board of Pharmacy told compounding pharmacies to stop compounding, distributing and dispensing copies of tirzepatide and semaglutide injections once FDA removed both from its shortage list, with May 22, 2025 the last date for outsourcing facilities on semaglutide.
Semaglutide in the states around Nevada
| State | Sell semaglutide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Wegovy for weight loss |
|---|---|---|---|---|
| Nevada | 19 | $39/moWellmedr | 44,949 | Medicaid Wegovy: No |
| Arizona | 19 | $39/moWellmedr | 8,154 | Medicaid Wegovy: No |
| California | 17 | $39/moWellmedr | 2,000,893 | Medicaid Wegovy: No |
| Idaho | 19 | $39/moWellmedr | 29,015 | Medicaid Wegovy: Not covered (KFF) |
| Oregon | 19 | $39/moWellmedr | 30,567 | Medicaid Wegovy: No |
| Utah | 19 | $39/moWellmedr | 10,366 | Medicaid Wegovy: Not confirmed (KFF) |



